Design and methodology of the CAPRICORN trial - a randomised double blind placebo controlled study of the impact of carvedilol on morbidity and mortality in patients with left ventricular dysfunction after myocardial infarction.
Clinical Research Initiative in Heart Failure, University of Glasgow, West Medical Building, G 12 8 QQ, Glasgow, UK.h.dargie@bio.gla.ac.uk
H J
HJ
Dargie
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D002227:Carbazoles / Q000627:therapeutic use*; D000077261:Carvedilol; D004311:Double-Blind Method; D006801:Humans; D015994:Incidence; D009203:Myocardial Infarction / Q000150:complications / Q000401:mortality*; D017410:Practice Guidelines as Topic; D011412:Propanolamines / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic / Q000379:methods*; D012107:Research Design; D012449:Safety; D015996:Survival Rate; D006113:United Kingdom / Q000453:epidemiology; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy / Q000209:etiology / Q000401:mortality*
D000319:Adrenergic beta-Antagonists; D002227:Carbazoles; D011412:Propanolamines; D000077261:Carvedilol